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Cancer of the esophagus has a poor prognosis, with 5fyear survival of only 5% to 10%.1 Less than 50% of esophageal cancers are considered 
operable at initial presentation, and metastatic disease 
is frequently found at the time of surgery.2 The overall 
5fyear survival rate after surgery for localized disease 
is 10 to 20%, with a median survival time of 12 to 15 
months.3f5
 18FfFDG PET (18ffluorodeoxyglucose positron 
emission tomography) is rapidly emerging as an imporf
tant tool in the noninvasive evaluation of patients with 
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BACKGROUND AND OBJECTIVES: 18f-fdG pet yields physiologic information that allows for identifying can-
cer based on altered tissue metabolism. the aim of this study was to prospectively validate the predictive value 
of positron emission tomography (pet) in squamous cell carcinoma (scc) of the esophagus treated by pre-opera-
tive chemotherapy followed by esophagectomy.
DESIGN AND SETTING: prospective efficacy and toxicity study of patients enrolled between January 1999 and 
september 2003.
PATIENTS AND METHODS: twenty-one patients with scc of the esophagus who were potentially resectable 
underwent 18f-fdG pet imaging before the first cycle of neoadjuvant chemotherapy and at least 14 days after 
the third cycle. a patient was classified as a metabolic responder when the metabolic activity of the primary 
tumor as measured by the maximum standardized uptake values had decreased by 50% or more at the time of 
the second 18f-fdG pet. 
RESULTS: the median age of the study cohort was 60 years with a range of 39-70 years; 12 patients were males 
and 9 were females. 18f-fdG pet had increased activity in the primary tumor in all patients. metabolic response 
occurred in 14/21 patients (66%), while 7/21 (33%) patients did not show a metabolic response. metabolic re-
sponders had a high clinical response rate (92%), a median progression free survival (pfs) of 16.4 months and a 
median overall survival (os) of 35.3 months. in contrast, prognosis was poor for metabolic non-responders with 
a clinical response rate of 42% (P=.025), a median pfs of 7.13 months (P=.032) and median os of 12 months 
(P=.038). 
CONCLUSION: our results demonstrate that changes in tumor metabolic activity after neoadjuvant chemo-
therapy predicts pfs and os in esophageal scc patients. 
different types of cancers. While conventional imaging 
methods such as CT determine the extent of disease 
based on associated morphologic changes, 18FfFDG 
PET yields physiologic information that allows for 
identifying cancer based on altered tissue metabolism.6 
Neoadjuvant chemotherapy in esophageal cancer aims 
at improving the resectability by shrinking the tumor 
locally and at improving survival by eradicating microf
metastatic disease. Early determination of nonfresponse 
to this therapy has an impact on treatment planning 
and may improve patient outcome by reducing unnecesf
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sary therapyfinduced toxicity.7 Furthermore, a change in 
therapy may improve the prognosis in those who do not 
benefit from such prefoperative chemotherapy. 
It has been shown that chemotherapyfinduced 
metabolic changes as measured by tumor glucose mef
tabolism predict recurrence and survival in esophageal 
cancer. Most of the studies included either patients with 
adenocarcinoma or mixed group of SCC and adenocarf
cinoma.8f9 In this prospective trial we studied the metaf
bolic response by 18FfFDG PET after neoadjuvant chef
motherapy in patients with squamous cell carcinoma of 
the esophagus (SCC) and correlated it with clinical and 
pathological response as well as survival. The aim of the 
trial was to find if the metabolic response assessed by 
18FfFDG PET can be used as a predictor of survival 
in this group of patients. We have reported earlier our 
results with neoadjuvant chemotherapy in SCC of the 
esophagus.10 We report the result of 18FfFDG PET 
evaluation in this group of patients.
PATIENTS AND METHODS
Between January 1999 and September 2003, patients 
with histologically confirmed localized SCC of the 
esophagus were enrolled into a prospective trial assessf
ing the efficacy and toxicity of 3 cycles of neoadjuvant 5f
fluorouracil, cisplatin and interferon αf2b in this group 
of patients. Patient selection and details of treatment 
were published earlier.10 All patients had a baseline hisf
tory and physical examination, esophagoscopy, barium 
swallow, CT scan of the chest and abdomen, bone scan, 
and 18FfFDG PET scan. Evaluation of response to chef
motherapy was done with esophagoscopy and biopsy, 
CT scan of chest and abdomen, and 18FfFDG PET scan 
at least 2 weeks after the last cycle of chemotherapy. 
Esophagectomy was done 3f5 weeks following the 
last cycle of chemotherapy. All patients were followed 
up for at least 5 years or death, whichever came first.
The 18FfFDG PET used for the PET studies was prof
duced by the Research Center at King Faisal Specialist 
Hospital according to the standard method. 18FfFDG 
PET images were performed by an ECAT EXACT 
(921) camera (CTI, Knoxville, Tenn) having a resoluf
tion of about 6 mm at fullfwidth at halffmaximum and 
a transaxial field of view of 16.2 cm. All patients fasted 
for at least 6 h before the PET scan. The serum glucose 
level was measured prior to intravenous administration 
of 370 MBq (10 mCi) of 18FfFDG. After intravenous 
injection of 18FfFDG, the patients were kept at rest in 
a quiet, dimly lit room for at least 50 minutes and talkf
ing, walking or other physical activities were avoided 
to reduce muscle uptake. Patients were scanned while 
lying supine along the central axis of the PET table. 
Table 1. Characteristics of the 21 patients.
Factor Number %
Sex
   Male 12 57
   Female 9 43
Age (years)
   Median 60
   range 39-70
Histological grade
   NOSa 1 4.8
   Well differentiated 2 9.5
   Moderately differentiated 14 66.7
   poorly differentiated 4 19
Performance Status (ECOG)b
   0 0 0
   1 15 71.4
   2 6 28.6
Tumor site at presentation
   Middle esophagus 8 38.1
   Lower esophagus 12 57.1
   Both 1 4.8
Lymphadenopathy on CT
   positive 2 9.5
   Negative 19 90.5
Tumor length (cm)
   Median (range) 6 (3-13)
aNOS= Not Otherwise Specified
bECOG = Eastern Cooperative Oncology Group
Table 2. Change in standardized uptake values (SUV) pre- and 
post-chemotherapy. 
Mean (SD) Range
Mean SUV pre-chemotherapy 6.88 (2.95) 3.3-16.6
Mean SUV post-chemotherapy 3.36 (2.91) 0.46-11.6
Maximum SUV pre-
chemotherapy 9.85 (3.01) 4.7-17.4
Maximum SUV post-
chemotherapy 3.39 (3.39) 0.81-12.2
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Seven sequential emission images were obtained from 
the head to the upper thigh, requiring 56 min in 2D 
mode (septa extended). Postfinjection transmission 
scans (3 minutes per bed position) were obtained with 
68Ge rod sources for attenuation correction. The emisf
sion and transmission scans were obtained in an alterf
nating sequence per bed position. Emission image were 
reconstructed into 128×128 transaxial slices using the 
OSEM (2 iterations, 8 subsets) method available in the 
system software, ECAT 7.2. The segmented attenuaf
tion correction technique was used as a method to corf
rect for attenuation.
Response criteria for local disease reported by Kelsen 
et al11 were used. A clinical complete response (CCR) 
was defined as complete radiological regression of visuf
alized tumor by barium esophagogram and CT scan. 
Partial response (PR) was defined as greater than 50% 
shrinkage of tumor as seen on repeat barium esophagof
gram with persistent histological evidence of the cancer 
endoscopically. Stable disease (SD) was defined as no 
change, less than 50% shrinkage of tumor or less than 
25% increase in tumor seen in barium esophagogram 
and progressive disease (PD) was defined as an increase 
of more than 25% in the tumor in barium esophagogram. 
A pathological complete response (PCR) was defined as 
the complete disappearance of all histological evidence 
of the malignancy in both the primary site and adjacent 
removed lymph nodes in the esophagectomy specimen. 
Metabolic response was assessed by comparing the mean 
and maximum standard uptake value (SUV) before and 
after chemotherapy. A decrease of 50% or more in SUV 
was considered a metabolic response. 
Overall survival (OS) was calculated from the date of 
first cycle of chemotherapy to the date of last follow up 
or death. Progression free survival (PFS) was calculated 
from the date of first cycle of chemotherapy to the date 
of progression, relapse or death. Descriptive statistics 
were presented as numbers and percentages (frequency 
distribution) based on intention to treat analysis. The 
KaplanfMeier method was used to determine survival 
curves. Statistical analysis was done using SPSS prof
gram version 11. 
RESULTS
Of the previously reported 30 patients enrolled in this 
study, 21 completed the prefplanned whole body 18Ff
FDG PET scan at baseline and after the last cycle of 
neoadjuvant chemotherapy. Patient characteristics are 
given in Table 1. The median age was 60 years with 
a range of 39f70 years. Median Eastern Cooperative 
Oncology Group (ECOG) performance status was 
one. Most of the cases (66.7%) showed moderately 
differentiated histology. Fiftyfseven percent of the 
cases had tumor located in the lower third of the 
esophagus. The mean and maximum SUV pref and 
postfchemotherapy are shown in Table 2. The perf
centage of change in the mean SUV from before to 
after chemotherapy ranged between 47% to 69% with 
a mean change of 49.8% and a standard deviation of 
39.7. The percentage of change of the SUV max from 
before to after chemotherapy was ranging between f




   Complete response 3 14.3
   No complete response 18 85.7
   partial response 13 61.9
   Stable disease 2 9.5
   Undetermined 2 9.5
   Not evaluable 1 4.8
Post-esophagectomy pathological 
response
   pathological complete response 4 19
   No pathological complete     
   response 13 57.1
   Nodal metastases 10 47.6
   Local disease 2 9.5
   Distant metastases 1 4.8
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Figure 1. progression-free survival according to mean SUV 
response.
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Figure 4. Overall survival according to maximum SUV response.
24.7% to 95.3% with a mean change of 54% and a 
standard deviation of 32.8.
Clinical response evaluation showed complete ref
sponse in 3 patients (14.3%) and partial response in 
13 patients (61.9%) for an overall response rate of 76.2 
%. Clinical response was undetermined in 2 patients 
because prefoperative endoscopic biopsy was not carf
ried out (Table 3). Seventeen patients underwent 
curative esophagectomy; of which 4 (19%) achieved 
pathological CR. Ten patients (47.6%) had positive 
nodal metastasis, 2 patients had local disease and 1 
had distant metastasis. Three patients who achieved a 
clinical partial response did not show a metabolic ref
sponse (<50% decrease in maximum SUV), and one 
patient who did not achieve clinical response showed 
a metabolic response (>50% decrease in maximum 
SUV). All the patients who achieved PCR showed 
a metabolic response except one who developed lof
cal recurrence in 9 months. Overall, 92% of metabolic 
responders had a clinical response while only 42% 
of metabolic nonresponders had a clinical response 
(P=.025).
With a median followfup period of 29.4 months 
(range of 3.1f62.3 months), the median progressionf
free survival was 10.8 month (95% confidence interf
val (CI), 2.6f16.3), and the median overall survival 
was 19.4 month (95% CI, 7.2f31.6) (Figure 1, 2). 
The 50% decrease in mean SUV between prefchef
motherapy and postfchemotherapy values showed a 
correlation with improved PFS but not OS. The mef
dian PFS was 7.1 months (95% CI, 4.9f9.4) and 16.5 
months (95% CI, 5.0f28.1) in patients with <50% and 
>50% decrease in mean SUV respectively (P=.048). 
The median OS were 12.0 month (95% CI, 5.7f18.4) 
and 35.3 months (95% CI 12.6f58.0) in patients with 
<50% and >50% decrease in mean SUV respectively 
(P=.221).
On the other hand, a more than 50% decrease in 
maximum SUV with prefoperative chemotherapy 
showed a correlation with improved PFS and OS 
(Figure 3, 4). The median PFS was 7.1 months (95% 
CI, 4.5f9.8) and 16.4 months (95% CI, 12.0f20.8) in 
patients with <50% and >50% decrease SUV max ref
spectively (P=.032). Median OS were 12.0 (95% CI 
11.4f12.6) and 35.3 months (95% CI, 12.2f58.4) in 
patients with <50% and >50% decrease in maximum 
SUV respectively (P=.038). Other prognostic factors 
that did have an impact on PFS or OS include PS, clinif
cal response to chemotherapy, gender and tumor size. 
Figure 5 shows an example of a metabolic responder 
patient and Figure 6 shows an example of metabolic 
nonfresponder patient.
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DISCUSSION
This trial is the first prospective trial to assess the pref
dictive value of 18FfFDG PET in patients with operable 
SCC of the esophagus treated with prefoperative chef
motherapy. We assessed the mean and maximum SUV 
and pref and postfchemotherapy. Our data showed imf
proved PFS and OS for patients who had a decrease 
in their maximum SUV by ≥50% with PFS/OS of 
16.4/35.3 months and 7.1/12.0 months in responders 
and nonfresponders, respectively. Several other studies 
have evaluated the role of 18FfFDG PET in assessing 
response after completion of prefoperative chemotherf
apy and chemoradiotherapy in patients with carcinoma 
of the esophagus. Brucher et al12,13 reported on 105 paf
tients with SCC of esophagus. In his trial, patients unf
derwent 18FfFDG PET before and after chemoradiof
therapy. The threshold pretherapyftofpostftherapy def
crease in standardized uptake value by 18FfFDG PET 
used to define metabolic responders was 52%. 18FfFDG 
PET responders showed a significantly longer median 
recurrenceffreefinterval and OS compared to nonfref
sponders (P=.04 and .002, respectively). 
Flamen et al9,14 showed prospectively that a decrease 
of more than 80% in the tumorftofliver uptake ratio aff
ter completion of neoadjuvant chemoradiotherapy pref
dicted response with a sensitivity of 71% and a specificf
ity of 82% in 36 patients with esophageal cancer (27 
cases of SCC and 9 of adenocarcinoma). 
In a study by Downey et al,15 39 patients with 
esophageal cancer (26 cases of adenocarcinoma and 13 
of SCC) underwent sequential 18FfFDG PET pref and 
postfinduction chemotherapy and 17 of them underf
went R0 esophagectomy. A maximum SUV reduction 
of more than 60% was correlated with an improved 2f
year DFS (67% vs. 38%, P=.055) but not OS (63% vs. 
89%, P=.088). 
Swisher et al16 published the prognostic relevance of 
18FfFDG uptake in 103 patients with localized esophaf
geal carcinoma (90 cases of adenocarcinoma and 13 of 
SCC) treated with neoadjuvant chemoradiotherapy. A 
postftreatment SUV of 4 or less was the most nonfinf
vasive predictor of longfterm survival (hazard ratio, 3.5, 
P=.04). The accuracy in predicting histopathologic no 
response was 76%, and the corresponding sensitivity 
and specificity were 62% and 84%, respectively. 
In a study by Cerfolio et al,17 48 patients with esophf
ageal cancer (41 cases of adenocarcinoma and 7 of SCC) 
underwent 18FfFDG PET/CT before and 3f4 weeks 
after neoadjuvant chemoradiotherapy. Retrospective 
analysis showed that 18FfFDG PET/CT predicted a 
complete response with a sensitivity of 87%, a specificf
ity of 88%, and an accuracy of 88%.
In a study by Kim et al,18 62 patients with esophageal 
cancer underwent prefoperative chemoradiotherapy 
(CRT). Pref and postfCRT 18FfFDG PET assessment 
was done. Complete metabolic responders by 18FfFDG 
PET showed the highest correlation with pathologic 
CR (concordance, 71%). Multivariate analysis revealed 
that complete metabolic response was significantly asf
sociated with better DFS and OS (P=.006 and P=.033, 
respectively). 
Port et al19 investigated retrospectively the ability 
of 18FfFDGPET to predict pathologic down staging, 
and survival in 62 patients with esophageal cancer (51 
cases of adenocarcinoma and 11 of SCC) who underf
Figure 5. Example of metabolically responsive patient. A 55-
year-old male with lower esophageal carcinoma before (A) and 
after (B) three cycles of neoadjuvant chemotherapy. Maximum 
SUV was 7.29 before therapy and 0.9 after therapy, indicating 
a complete metabolic response. The patient survived for 66 
months.
Figure 6. Example of metabolically non-responsive patient. A 55-
year-old male with lower esophageal carcinoma before (A) and 
after (B) three cycles of neoadjuvant chemotherapy. Maximum 
SUV was 11.4 before therapy and 7.4 after therapy indicating no 
metabolic response. The patient survived for 5.8 months.
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went preoperative chemotherapy.19 Patients with a 50% 
or greater reduction in the maximum SUV of their prif
mary tumor had significantly better disease survival than 
did patients with a less than 50% reduction in maximum 
SUV (median DFS, 35.5 mo vs. 17.9 mo, P=.03). 
In a study published by Smithers et al 20 on 45 
patients with adenocarcinoma of the esophagus, 18Ff
FDG PET was performed before treatment (22 receivf
ing neoadjuvant chemotherapy and 23 chemoradiation 
therapy) and 3f6 weeks after completion of platinumf
based chemotherapy.20 The authors found no correlaf
tion between the 18FfFDG PET response and the hisf
topathologic response in their study cohort.
Heterogeneity is observed in the amount of diff
ference used between the 18FfFDG PET value 
pref and postftherapy, ranging from 35%f more than 
60%.14,19,21,22 Some investigators used an absolute SUV 
value post therapy of 4 as a predictor of response.16 
Regardless of the method used 18FfFDG PET proved 
to be a useful tool in predicting PFS and OS in this 
group of patients. Other investigators have concluded 
that a high maximum SUV max on baseline 18FfFDG 
PET scan in patients undergoing surgery or prefopf
erative therapy predicts poor survival. The two reports 
published in this regard used different cutfoff for the 
maximum SUV, were retrospective and did not have 
uniform prefoperative therapy nor histology, and acf
cordingly their data will have to be validated in a prof
spective setting.17,23 
In summary, our result confirms the predictive benf
efit of 18FfFDG PET scan in patients with SCC of the 
esophagus treated by prefoperative chemotherapy.
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